Inhibrx Biosciences, Inc. (INBX) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $77.23
• Market Cap: $1.17B
• EPS: $-11.96
• 52-Week High: $94.56
• 52-Week Low: $10.80

Market Sentiment

Inhibrx Biosciences, Inc. currently has a Bearish sentiment score of -0.25.

About Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. is a clinical-stage biotechnology company headquartered in La Jolla, California, focused on developing cutting-edge biological therapeutics for cancer and other serious diseases. With a diverse pipeline that features monoclonal antibodies and multi-specific therapeutics, Inhibrx aims to enhance treatment efficacy and safety, ultimately improving patient outcomes. By harnessing its proprietary technologies, the company is uniquely positioned to drive innovation in the...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Inhibrx Biosciences, Inc. and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does INBX pay dividends?

Inhibrx Biosciences, Inc. (INBX) does not currently pay a regular dividend.

What is INBX's market cap?

Inhibrx Biosciences, Inc. (INBX) has a market capitalization of $1.17B with a current stock price of $77.23.